[{"from": "human", "value": "Provide a brief overview of this molecule. [C][O][C][=C][Branch2][Ring2][#Branch2][C][=C][C][=Branch1][Ring2][=C][Ring1][=Branch1][C][=Branch2][Ring1][=N][=N][C][=Branch1][Ring2][=N][Ring1][#Branch1][N][C][C][N][Branch1][Branch1][C][C][Ring1][=Branch1][C][=Branch1][C][=O][C][C][C][C][O][Ring1][Branch1][N][O][C].[O].[O].[Cl]"}, {"from": "gpt", "value": "The molecule is the hydrochloride salt form of terazosin, a quinazoline derivative with adrenergic antagonistic property. Terazosin hydrochloride selectively inhibits alpha-1 adrenergic receptors, resulting in vasodilation leading to decreased peripheral vascular resistance and a reduced venous return to the heart as well as decreased urethral resistance, which potentially improving urine flow and symptoms related to benign prostatic hyperplasia. In addition, terazosin decreases low-density lipoproteins (LDL) and triglycerides while increasing the concentration of high-density lipoproteins (HDL)."}]